Secukinumab as a Potential Trigger of Inflammatory Bowel Disease in Ankylosing Spondylitis or Psoriatic Arthritis Patients

^aThis one patient had not yet reached 16 weeks after treatment initiation of secukinumab at the time of analysis.

Data are n (%). ^aPossible: gastrointestinal symptoms not fulfilling definite or probable criteria. ^bProbable: as per definite, but without biopsy/objective confirmation. ^cDefinite: objective evidence of IBD, clear temporal association, resolution of symptoms on drug withdrawal, no alternative explanation more likely.

Authors and Disclosures

Ioana A. Onac¹, Benjamin D. Clarke¹, Cristina Tacu², Mark Lloyd³, Vijay Hajela², Thomas Batty², Jamie Thoroughgood⁴, Sandra Smith³, Hannah Irvine⁵, Diane Hill⁶, Grace Baxter⁷, Natalie Horwood⁷, Suma Mahendrakar⁷, Rizwan Rajak⁷, Sian Griffith⁴, Patrick D. W. Kiely^6,8 and James Galloway<sup>9

1</sup>Department of Academic Rheumatology, King's College London, London, ²Department of Rheumatology, Brighton and Sussex University Hospital, Brighton, ³Department of Rheumatology, Frimley Park Hospital, Frimley, ⁴Department of Rheumatology, East Surrey Hospital, Redhill, ⁵Department of Rheumatology, Royal Berkshire NHS Foundation Trust, Reading, ⁶Department of Rheumatology, St George's University Hospitals NHS Foundation Trust, London, ⁷Department of Rheumatology, Croydon University Hospital, Croydon, ⁸Institute of Medical and Biomedical Education, University of London St George's and ⁹Centre for Rheumatic Diseases, King's College London, London, UK

Correspondence to
Ioana A. Onac, Department of Academic Rheumatology, King's College London, Denmark Hill, Brixton, London SE5 9RS, UK. E-mail: i.onac@nhs.net

Disclosure statement
The authors have no conflict of interest to declare but I.A.O. has received education support to attend conference and courses from Abbvie and Novartis. C.T. has received honoraria from Novartis Pharmaceutical UK for a speaker fee and education support for a course from Novartis. M.L. has received departmental support form Novartis. N.H. has received educational support for attending conferences from Lilly and Abbvie. S.M. has received education support to attend conferences from Lilly. R.R. has received honoraria for speaker fee from Eli Lilly, Amgen, Internis, Roche, UCB and Abbvie, and honoraria for chairing from Roche, Novartis, Eli Lilly and UCB. P.D.W.K. has received honoraria from Abbvie, BMS, Gilead, Lilly, Novartis and Sanofi, and member of speaker's bureau from Abbvie, BMS, Lilly, Novartis and Sanofi. J.G. has received honoraria, speaker fees, travel support and grants from Lilly, Abbvie, BMS, Celgene, Janssen, Pfizer, UCB and Sanofi.

Sidebar

Rheumatology key Messages

• The absolute rates of new IBD in patients starting secukinumab are low.

• IBD screening prior to starting anti-IL-17 is not supported, particularly in PsA patients.

• The risk of IBD flares on secukinumab is higher in AS patients.